盐酸氨溴索注射液联合头孢哌酮舒巴坦钠治疗重症社区获得性肺炎的疗效

目的 探讨盐酸氨溴索注射液联合头孢哌酮舒巴坦钠治疗重症社区获得性肺炎（SCAP）的临床疗效和安全性.方法 将60例SCAP患者按随机数字表法分为观察组和对照组,每组30例.对照组给予常规治疗,同时给予头孢哌酮舒巴坦钠2.0 g加入0.9％氯化钠溶液100 mL中静脉滴注,2次·d-1;观察组在对照组的基础上,给予盐酸氨溴索注射液30 mg加入0.9％氯化钠溶液100 mL中静脉滴注,2次·d-1.2组患者均10 d为1个疗程.对2组患者的疗效,C反应蛋白、IL-6、IL-10水平的变化及不良反应进行比较.结果 观察组总有效率为96.67％,对照组总有效率为73.33％,2组比较差异有统计学意义（P＜0.05）.治疗10 d后观察组C反应蛋白、IL-6明显低于对照组,IL-10明显高于对照组（均P＜0.05）.2组在治疗期间均未见明显的不良反应.结论 氨溴索联合头孢哌酮舒巴坦治疗SCAP,能明显地减轻患者的临床症状和体征,减轻炎性反应,提高临床治疗效果,且无明显的不良反应.

Effects of Ambroxol Hydrochloride Combined with Sulbactam Cefoperazone on Severe Community Acquired Pneumonia

Objective To investigate the clinical effects of ambroxol hydrochloride combined with sulbactam cefoperazone on severe community acquired pneumonia （SCAP）. Methods Sixty patients with SCAP were randomly divided into observation group and control group, with 30 patients in each group. All patients received conventional therapy （oxygen inhalation, expectorant, nutritional support and symptomatic treatment） and intravenous infusion of sulbactam cefoperazone 2.0 g in 100 mL of 0.9% sodium chloride solution （twice per day）. On this basis, the observation group was given intravenous infusion of ambroxol hydrochloride 30 mg in 100 mL of 0.9% sodium chloride solution（twice per day）. The course of therapy was 10 days. Curative efficacy, levels of C-reactive protein （CRP）, interleukin-6 （IL-6） and interleukin-10（IL-10） and adverse reactions were compared between the two groups. Results The total effective rate in observation group was significantly higher than that in control group （96.67% vs 73.33%, P〈0.05）. Furthermore, ambroxol hydrochloride decreased CRP and IL-6 levels but increased IL-10 levels compared with control group after treatment for 10 days （P〈 0.05）. No adverse reactions were found in both groups. Conclusion Ambroxol hydrochloride combined with sulbactam cefoperazone reduces clinical symptoms and signs, alleviates inflammatory response, improves clinical outcomes, and does not result in adverse reactions in patients with SCAP.